Retrospective database analysis focused on Famotidine but also showing results for HCQ users, with unadjusted mortality RR 0.85, p<0.001 (13.6% vs. 16.1%).
risk of death, 15.4% lower, RR 0.85, p < 0.001, treatment 686 of 5,047 (13.6%), control 3,923 of 24,404 (16.1%), NNT 40.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
This study is excluded in the after exclusion results of meta
unadjusted results with no group details.
Shoaibi et al., 24 Sep 2020, retrospective, database analysis, USA, preprint, 5 authors.